about
Optimal management of constipation associated with irritable bowel syndromeEpidemiology and natural history of gastroesophageal reflux disease.Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations.The natural history of gastro-esophageal reflux disease: a comprehensive review.Vonoprazan fumarate for the management of acid-related diseases.Reduction of hexavalent chromium by fasted and fed human gastric fluid. I. Chemical reduction and mitigation of mutagenicity.Impedance-detected Symptom Association and Number of Reflux Episodes as Pre-treatment Parameters That Predict Outcomes of Gastroesophageal Reflux Disease Patients.Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD.Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD.Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease.Relevance of Measuring Substances in Bronchoalveolar Lavage Fluid for Detecting Aspiration-associated Extraesophageal Reflux DiseasePathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis.Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn.Drugs for improving esophageal mucosa defense: where are we now and where are we going?Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution.Anti-Tumor Necrosis Factor Antibodies for Prevention of Crohn's Disease Recurrence After Surgery: More Than a Hope.Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis.Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index.Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value?Measurement of oro-caecal transit time by magnetic resonance imaging.Complexity and diversity of gastroesophageal reflux disease phenotypes.A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD).Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux diseaseCharacteristics of gastro-esophageal reflux episodes in Barrett’s esophagus, erosive esophagitis and healthy volunteersCharacteristics of Reflux Episodes and Symptom Association in Patients With Erosive Esophagitis and Nonerosive Reflux Disease: Study Using Combined Impedance–pH Off TherapyOverweight is a risk factor for both erosive and non-erosive reflux diseaseThe added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux diseaseHyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver diseaseHepatocellular carcinoma in patients with cryptogenic cirrhosisComment on "impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis" by Marzio Frazzoni et al. [Digestive and Liver Disease 2014;46:596-602]Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data
P50
Q35586543-E32E9A4C-B222-44B5-B45F-D5C8513926B5Q38755717-E44B0817-19B4-4321-BC55-F877FBD5F15FQ38900694-DBAEC369-703F-4D7E-9E43-C2670EB4188EQ39013080-CE5E17AB-A51F-487F-A58D-D5E9D04F1BDBQ39402205-5242E737-4215-4D7E-A635-232E0B6FD86CQ39610174-69D911C0-8AC2-4138-9D7B-C4A7C62475CEQ39665561-F50897A8-9D6A-412A-B406-36DCB3DBB7FFQ40178069-903ACDB3-B3B9-4467-9A52-B1757DA169CDQ40575149-32D950C2-DA59-4141-88A4-CE876046858EQ40903234-A3D44526-862A-4D71-8C89-AD982D8640ADQ41878793-4106277A-3584-41C9-921B-F396D0648D5CQ42365923-5A4D371D-6043-41A2-ADF4-D42865965422Q42385643-3B94CD17-1C78-4230-B60C-60ED895DA6F3Q42513103-85B4679B-2807-480D-B597-9AB31136A6D2Q44286888-69E01767-1164-49A3-A6E5-52F6F1A23EAAQ45969659-33A85014-7BAA-4B08-84F8-8A0DF5EF169FQ47573052-568A6DEE-2F18-4BB7-B1D1-0963723885DDQ48036284-14DFA135-14DD-481B-A222-4ACC9212E806Q48172806-DDB7346B-7771-4965-8219-16030B8F3523Q51059072-1D2D96B6-37B9-48CC-B56C-284EF596A3D8Q51608276-6B4B2E83-5794-4DFA-A274-2DD45E00B375Q51667996-7C7BF67C-2C10-400A-BA57-0059EF31ADB4Q52706292-7BD582F5-7728-43A0-A2D4-3BCCEF722A17Q53731083-89CBE54F-85FB-4BEA-8D98-752FD05703FFQ60619292-803DA789-B48F-415C-B8DA-03E871D447F0Q60619296-1C1D4D93-045D-429B-B2CC-EFBD1BDDE777Q60619299-8B836855-2402-4CE2-8CF0-CCCBA2EEEDF8Q63199371-004E9AE9-D450-4FB3-AFBD-6FD70AFEAE09Q63199372-01AE87BE-0DDB-47CC-A150-A9D0F8E474CDQ83184796-5E998AC5-5843-4D93-8794-EEDE9D298CD3Q83776267-27246324-DCE7-40BB-8905-5ECBA6AD1EDCQ87481178-9224EA8F-A60A-4D17-A0AE-46A0F5F558BAQ94452940-CB52F0D0-FE62-481F-8A76-E4E41868E80D
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Elisa Marabotto
@ast
Elisa Marabotto
@en
Elisa Marabotto
@es
Elisa Marabotto
@nl
type
label
Elisa Marabotto
@ast
Elisa Marabotto
@en
Elisa Marabotto
@es
Elisa Marabotto
@nl
prefLabel
Elisa Marabotto
@ast
Elisa Marabotto
@en
Elisa Marabotto
@es
Elisa Marabotto
@nl
P106
P1153
12806665400
P21
P31
P496
0000-0003-4507-8605